PHASE 3B ProvIDHe
6 May 2026
Ivosidenib for IDH1-mutant, advanced cholangiocarcinoma Real-world data from the phase 3b ProvIDHe study
Where evidence meets expertise
STudy in the Picture (STiP) brings clinical research into sharp focus through concise, expert-driven summaries. Each STiP distils a single clinical study into its essential elements, from rationale and design to key results and clinical relevance, without compromising scientific depth.
Two formats, one mission
STiP │ Congress Highlights
Tied to the most important oncology congresses, these STiPs go beyond the headline results. Developed alongside expert video interviews recorded on-site, each piece unpacks study rationale, design, and key findings, and connects you to the full discussion via the congress video page.
KEYNOTE-024
6 May 2026
Durable survival withpembrolizumab monotherapy in metastatic NSCLC with high levels of PD-L1 expression
DESTINY-Breast03 trial
6 May 2026
Trastuzumab deruxtecan solidifi ed as preferred 2nd line treatment for patients with HER2- positive, metastatic breast cancer
Final analysis from the DESTINY-
Breast03 trial
KEYNOTE-581: updated results ofthe CLEAR study
6 May 2026
Lenvatinib plus pembrolizumab confi rmed as a standard-of-care treatment for patients with advanced RCC regardless of the presence of bone metastases1
STiP │ Key Publications
Not every breakthrough happens at a congress. These STiPs focus on landmark journal publications, giving pivotal studies the depth they deserve. Where available, an expert video interview adds further insight and clinical perspective.
NEW INSIGHTS FROM THE PHASE III SUNLIGHT TRIAL
6 May 2026
Enhancing clinical cancer research through the sharing of data and biospecimens
Enhancing clinical cancer research through sharing of data and biospecimens
6 May 2026
Enhancing clinical cancer research through the sharing of data and biospecimens
